Motilal Oswal Large and Midcap Fund - Dir (G) vs Nippon India Pharma Fund - Direct (G)

Motilal Oswal Large and Midcap Fund - Dir (G) vs Nippon India Pharma Fund - Direct (G)

stock1

Motilal Oswal Large and Midcap Fund - Dir (G)

6.09%

stock2

Nippon India Pharma Fund - Direct (G)

7.4%

Loading chart...

About Fund

-

-

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Very High Risk

500

18413.16

0.98

38.6717

September 27, 2019

0

Very High Risk

5000

9044.23

1.12

634.5023

January 1, 2013

1

19.44 %

22.73 %

6.09 %

14.01 %

19.35 %

7.4 %

Aditya Khemani

PGDBM,B.Com,(Hons)

Over 14 Years experience in Research. HSBC Asset Management (India) Private Limited from October 2007. SBI Funds Management India Private Limited- Senior Manager Equity research From March 2007 to September 2007. Prudential ICICI Asset Management Company India Private Limited as Assistant Manager - Equity Research from December 2005 to February 2007. Morgan Stanley Advantage Services Private Limited as Research Associate from May 2005 to November 2005.

Ajay Khandelwal

MBA, Bachelor of Engineering

Around 14 years of Experience including 9 years in Mutual Fund industry BOI AXA Investment Managers Private Limited ( April 2010 To Present) B&K Securities ( January 2008 To April 2010) Infosys (June 2005 To December 2007)

Niket Shah

Masters in Business Administration (MBA-Finance)

Niket Shah has 9 years of overall experience. Motilal Oswal Asset Management Company Ltd. - Vice President - Associate Fund Manager Motilal Oswal Securities Ltd - Head of Midcaps Research Edelweiss Securities Ltd. - Research Analyst - Midcaps Religare Capital Markets Ltd. - Associate Research Analyst - Midcaps

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Get your FAQs right